Rebecca Viner1, Kirsten M Fiest2, Andrew G M Bulloch3, Jeanne V A Williams1, Dina H Lavorato1, Sandra Berzins2, Nathalie Jetté4, Luanne M Metz5, Scott B Patten6. 1. Department of Community Health Sciences, University of Calgary, Canada. 2. Department of Community Health Sciences, University of Calgary, Canada; Mathison Center for Mental Health Research & Education, Hotchkiss Brain Institute, University of Calgary, Canada. 3. Department of Community Health Sciences, University of Calgary, Canada; Department of Psychiatry, University of Calgary, CANADA; Mathison Center for Mental Health Research & Education, Hotchkiss Brain Institute, University of Calgary, Canada. 4. Department of Community Health Sciences, University of Calgary, Canada; Department of Clinical Neurosciences and the Hotchkiss Brain Institute, University of Calgary, Canada. 5. Department of Clinical Neurosciences and the Hotchkiss Brain Institute, University of Calgary, Canada. 6. Department of Community Health Sciences, University of Calgary, Canada; Department of Psychiatry, University of Calgary, CANADA; Mathison Center for Mental Health Research & Education, Hotchkiss Brain Institute, University of Calgary, Canada. Electronic address: patten@ucalgary.ca.
Abstract
OBJECTIVE: The prevalence of depression in multiple sclerosis (MS) is known to be elevated, but nearly all available studies have estimated period prevalence. The objective of this study was to estimate the point prevalence of depression in a representative community sample using the Patient Health Questionnaire, Brief (PHQ-9). METHODS: The data source for this study was the Survey of Living with Neurological Conditions in Canada, which was derived from a representative sample of household residents. RESULTS: The sample included 630 respondents with MS. With application of the standard PHQ-9 cut point (10+), the prevalence of depression was 26.0% (95% confidence interval 18.9%-33.0%). Depressed subjects had lower quality of life; an increased frequency of suicidal ideation; and more often reported a negative disease course, high stress, low social support and stigmatization. CONCLUSIONS: This study adds to the existing literature by providing point prevalence data: in any 2-week period, about one quarter of community residents with MS experience substantial levels of depressive symptoms.
OBJECTIVE: The prevalence of depression in multiple sclerosis (MS) is known to be elevated, but nearly all available studies have estimated period prevalence. The objective of this study was to estimate the point prevalence of depression in a representative community sample using the Patient Health Questionnaire, Brief (PHQ-9). METHODS: The data source for this study was the Survey of Living with Neurological Conditions in Canada, which was derived from a representative sample of household residents. RESULTS: The sample included 630 respondents with MS. With application of the standard PHQ-9 cut point (10+), the prevalence of depression was 26.0% (95% confidence interval 18.9%-33.0%). Depressed subjects had lower quality of life; an increased frequency of suicidal ideation; and more often reported a negative disease course, high stress, low social support and stigmatization. CONCLUSIONS: This study adds to the existing literature by providing point prevalence data: in any 2-week period, about one quarter of community residents with MS experience substantial levels of depressive symptoms.
Authors: Taoufik Alsaadi; Khadija El Hammasi; Tarek M Shahrour; Mustafa Shakra; Lamya Turkawi; Abdulla Mudhafar; Lina Diab; Mufeed Raoof Journal: Mult Scler Int Date: 2015-07-09